NEOGENOMICS INC (NEO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 250M 500M 750M FY10: 34.4M FY11: 43.5M FY12: 59.9M FY13: 66.5M FY14: 87.1M FY15: 99.8M FY16: 231.8M FY17: 240.3M FY18: 276.7M FY19: 408.8M FY20: 444.4M FY21: 484.3M FY22: 509.7M FY23: 591.6M FY24: 660.6M FY25: 727.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 150M 300M 450M FY10: 15.8M FY11: 19.4M FY12: 26.8M FY13: 31.7M FY14: 40.7M FY15: 43.8M FY16: 98.1M FY17: 102M FY18: 127.3M FY19: 196.8M FY20: 185.9M FY21: 187.1M FY22: 187.9M FY23: 244.6M FY24: 290.1M FY25: 314.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-180M -120M -60M 0 60M 120M 180M FY10: -3M FY11: -409K FY12: 1.2M FY13: 3.2M FY14: 2.2M FY15: -5.6M FY16: 2.2M FY17: 2.9M FY18: 10M FY19: 13M FY20: -14M FY21: -118.8M FY22: -157.6M FY23: -107.7M FY24: -92.1M FY25: -115.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-150M -100M -50M 0 50M 100M 150M FY10: -3.3M FY11: -1.2M FY12: 65K FY13: 2M FY14: 1.1M FY15: -2.5M FY16: -6.1M FY17: -396K FY18: 2.6M FY19: 8M FY20: 4.2M FY21: -8.3M FY22: -144.2M FY23: -88M FY24: -78.7M FY25: -108M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150M 300M 450M FY16: 133.7M FY17: 138.3M FY18: 149.5M FY19: 212M FY20: 258.6M FY21: 297.3M FY22: 321.8M FY23: 347M FY24: 370.5M FY25: 413M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M FY10: -2.1M FY11: 69K FY12: -492K FY13: 2.2M FY14: 9.4M FY15: 6.4M FY16: 21.5M FY17: 18M FY18: 44.8M FY19: 23.4M FY20: 1.5M FY21: -26.7M FY22: -66M FY23: -2M FY24: 7M FY25: 5.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-105M -70M -35M 0 35M 70M 105M FY10: -3M FY11: -828K FY12: -3.1M FY13: 216K FY14: 5.7M FY15: 4.2M FY16: 13.9M FY17: 4.3M FY18: 30.5M FY19: 3.3M FY20: -27.6M FY21: -90.9M FY22: -96.9M FY23: -30.7M FY24: -34M FY25: -21.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 50M 100M 150M FY11: 42.8M FY12: 48.7M FY13: 52.8M FY14: 56M FY15: 60.5M FY16: 77.5M FY17: 79.4M FY18: 91.6M FY19: 103.6M FY20: 111.8M FY21: 120M FY22: 124.2M FY23: 125.5M FY24: 126.7M FY25: 128.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.11 -0.07 -0.04 0.00 0.04 0.07 0.11 Q4 '10: -0.09 Q1 '11: -0.09 Q2 '11: -0.07 Q3 '11: -0.04 Q4 '11: -0.03 Q2 '13: -0.01 Q3 '13: 0.03 Q4 '13: 0.05 Q1 '14: 0.05 Q2 '14: 0.05 Q3 '14: 0.02 Q4 '14: 0.02 Q1 '15: 0.01 Q2 '15: 0.00 Q3 '15: 0.01 Q4 '15: -0.04 Q1 '11 Q3 '11 Q2 '13 Q4 '13 Q2 '14 Q4 '14 Q2 '15 Q4 '15

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.